Neha Mehta-Shah, MD, MSCI

Bone Marrow Transplant Specialist, Medical Oncologist

Neha Mehta-Shah

Appointment Options

Whether you’re seeking a new patient appointment or exploring treatment options and looking for a second opinion, our Siteman care coordinators are ready to assist you.

My Locations

Gary C. Werths Building at Siteman Cancer Center

Gary C. Werths Building at Siteman Cancer Center

On WashU Medicine Campus
4500 Forest Park Avenue, Saint Louis, MO 63108
Siteman Cancer Center at Barnes-Jewish West County Hospital

Siteman Cancer Center at Barnes-Jewish West County Hospital

Medical Office Building 2, 10 Barnes West Drive, Creve Coeur, MO 63141

Expertise & Training

Video thumbnail for Neha Mehta-Shah, MD

Watch video on YouTube

Neha Mehta-Shah, MD

5 mins

Neha Mehta-Shah, MD Medical Oncologist at Siteman Cancer Center discusses their approach to cancer care.

Clinical Expertise

  • Non-Hodgkin lymphomas, including peripheral T-cell lymphoma and cutaneous lymphomas

Primary Academic Title

Associate Professor of Medicine, Division of Oncology, WashU Medicine

Board Certification

  • 2012: American Board of Internal Medicine
  • 2016: American Board of Medical Oncology
  • 2016: American Board of Hematology

Training

  • 2009 - 2012: Resident, New York Presbyterian - Weil Cornell Medical Center, New York, NY
  • 2012 - 2013: Chief Medical Resident, Memorial Sloan-Kettering Center, New York, NY
  • 2013 - 2016: Fellow, Memorial Sloan-Kettering Cancer Center, New York, NY

Education

  • 2009: MD, Northwestern University, Chicago, IL

Research & Selected Publications

Research Interest

Clinical trials including novel therapies for patients with lymphoma including peripheral and cutaneous T-cell lymphomas

Research Publications

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma
Authors:

Mehta-Shah N, Zinzani PL, Jacobsen ED, one or more additional authors omitted Horwitz SM

Journal & Year:

J Clin Oncol | 2026

Multiomic study of cutaneous T-cell lymphoma reveals single-cell clonal evolution in progression and therapy resistance
Authors:

Dorando HK, Andrews JM, Khatavkar OU, one or more additional authors omitted Mehta-Shah N, Payton JE

Journal & Year:

Blood | 2026

SOHO State of the Art Updates and Next Questions | Optimizing Frontline Treatment for Peripheral T-Cell Lymphoma
Authors:

Akkad N, Mehta-Shah N

Journal & Year:

Clin Lymphoma Myeloma Leuk | 2026

A randomized phase 2 study of ipilimumab, nivolumab, and brentuximab vedotin in patients with relapsed Hodgkin lymphoma
Authors:

Diefenbach CS, Jegede O, Wang V, one or more additional authors omitted Mehta-Shah N, one or more additional authors omitted Kahl BS

Journal & Year:

Blood | 2026

Prognosis and treatment of plasmablastic lymphoma in the United States: a multicenter retrospective study
Authors:

Hamby M, Egleston BL, Frosch ZAK, one or more additional authors omitted Mehta-Shah N, one or more additional authors omitted Barta SK

Journal & Year:

Blood Cancer J | 2026

PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX study
Authors:

Thompson C, Trněný M, Morschhauser F, one or more additional authors omitted Mehta-Shah N, one or more additional authors omitted Friedberg JW

Journal & Year:

Blood | 2026

Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma
Authors:

Morschhauser F, Salles G, Sehn LH, one or more additional authors omitted Mehta-Shah N, one or more additional authors omitted Flowers CR

Journal & Year:

J Clin Oncol | 2025

ASTCT and USCLC clinical practice recommendations for allogeneic stem cell transplant in mycosis fungoides and Sézary syndrome
Authors:

Goyal A, O'Leary D, Dabaja B, one or more additional authors omitted Mehta-Shah N, one or more additional authors omitted Foss F

Journal & Year:

J Am Acad Dermatol | 2025